Feb 19 (Reuters) – German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna’s COVID-19 vaccine mNEXSPIKE infringes a patent related to BioNTech and Pfizer’s competing shot Comirnaty.
The lawsuit said that mNEXSPIKE, Moderna’s next-generation COVID shot approved by the U.S. Food and Drug Administration in 2025, violates BioNTech’s rights in technology for a streamlined messenger RNA-based vaccine design that can be given to patients at a lower dosage.
Moderna sued BioNTech and its partner Pfizer for patent infringement over Comirnaty in 2022, in a lawsuit that is ongoing. The cases are among a wave of patent lawsuits from biotech companies seeking royalties for the technology used in the blockbuster vaccines.
A Moderna spokesperson said that the company would defend itself against BioNTech’s case. BioNTech did not immediately respond to a request for comment on the new lawsuit.
Spokespeople for Pfizer, which is not directly involved in the lawsuit, also did not immediately comment.
mNEXSPIKE is expected to account for 55% of Moderna’s COVID vaccine revenue through the 2025-26 respiratory virus season, BioNTech’s lawsuit said.
COVID vaccine revenues have dropped sharply since the height of the pandemic, when Moderna’s Spikevax and Pfizer and BioNTech’s Comirnaty earned the companies billions in revenue. Vaccine revenues in general have also slumped following U.S. President Donald Trump’s appointment of vaccine skeptic Robert F. Kennedy Jr. as health secretary.
(Reporting by Blake Brittain in Washington; editing by Barbara Lewis and Deepa Babington)
Comments